San Diego, CA, June 23, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ:RNA) the Dutch biopharmaceutical
company focusing on rare diseases with a high unmet medical need,
today announced that Hans GCP Schikan, Chief Executive Officer of
Prosensa, has been appointed to the Biotechnology Industry
Organization's (BIO) Emerging Companies Section Governing Board.
"As a global expert in rare diseases and with invaluable
experience steering a company from early stage through to a
publicly listed company nearing commercialization, we welcome Mr.
Schikan to BIO's board. His expertise in these areas, together with
his pioneering experience in the Duchenne Muscular Dystrophy (DMD)
space, will prove essential as we continue to work with regulators
globally to expedite treatment options for major unmet medical
needs," said Cartier Esham, BIO's Executive Vice President of
In addition to his role as Chief Executive Officer of Prosensa,
Mr. Schikan also serves as Non-executive Director of Swedish Orphan
Biovitrum A.B., Executive Board Member of the Dutch Top Institute
Pharma, and Member of the Core Team of the Dutch Top Sector Life
Sciences & Health. He is also past Chairman of Nefarma, the
Dutch Association of Research Based Pharmaceutical
"I am delighted to be joining the BIO Emerging Companies Section
Governing Board and work alongside other industry leaders to
continue to advance the biotechnology industry", said Mr.
"BIO's work is crucial to helping emerging companies thrive in
this challenging space. The work BIO has accomplished in recent
years with significant contributions to the JOBS Act and FDASIA
have enabled innovators like Prosensa to more easily access the
capital markets and work more collaboratively with regulators. I
look forward to drawing from my experience to continue to promote
innovation for the benefit of patients and industry," he said.
Notes to editors
About Hans GCP Schikan, Chief Executive
Hans Schikan, 55, has served as Chief Executive Officer of
Prosensa N.V. since January 2009. Mr. Schikan has more than 25
years of senior managerial experience in the pharmaceutical and
biotechnology industries. From May 2004 until January 2009, Mr.
Schikan worked at Genzyme Corporation in various executive roles,
including Vice President of Global Marketing and Strategic
Development for its rare genetic disease franchise. In this
position he oversaw the launch of various orphan drugs globally.
Prior to Genzyme, Mr. Schikan worked at Organon International from
1986 to 2004 in various senior business roles across different
geographies, including managing director positions in multiple
countries. Mr. Schikan also serves as Non-executive Director of
Swedish Orphan Biovitrum A.B., Executive Board Member of the Dutch
Top Institute Pharma, and Member of the Core Team of the Dutch Top
Sector Life Sciences & Health. He is also past Chairman of
Nefarma, the Dutch Association of Research Based Pharmaceutical
Industry. Mr. Schikan holds a Pharm.D. degree from the University
of Utrecht, the Netherlands.
About Prosensa Holding N.V.
Prosensa (NASDAQ:RNA) is a Dutch biotechnology company engaged
in the discovery and development of RNA-modulating therapeutics for
the treatment of genetic disorders. Its primary focus is on rare
neuromuscular and neurodegenerative disorders with a large unmet
medical need, including Duchenne muscular dystrophy (DMD), Myotonic
dystrophy and Huntington's disease.
Prosensa's current portfolio includes six compounds for the
treatment of DMD, all of which have received orphan drug status in
the United States and the European Union. The compounds use an
innovative technique called exon-skipping to provide a personalized
medicine approach to treat different populations of DMD patients.
CONTACT: Prosensa Holding N.V.Celia Economides, Senior Director IR & Corporate Communications
Source: Prosensa Holding N.V.